Zepp Health Corporation
NYSE:ZEPPConsumer Electronics
-$0.03 today
- Market cap
- $50.84M
- Beta
- 1.78
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$282.07
Volume 0.04M
Average 0.13M
ZEPP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Zepp Health CorporationNYSE: ZEPP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was CN¥0, compared with CN¥89.89M a year earlier. Trailing-twelve-month research & development was CN¥234.24M. Over 3 fiscal years it compounded at -15.5% a year.
Context
- Research & development amounted to 17.5% of revenue in FY2025, down 7.8 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near CN¥0 or moves back toward the trailing-twelve-month quarterly average of CN¥58.56M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CNY · from the income statement
- Latest · FY2025
- 317.73M CNY
- Year-over-year change
- -5.7%
- 4-year CAGR
- -11.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 317.73M | -5.7% |
| FY2024 | 2024-12-31 | 337.07M | -7.5% |
| FY2023 | 2023-12-31 | 364.53M | -30.7% |
| FY2022 | 2022-12-31 | 526.2M | +3.5% |
| FY2021 | 2021-12-31 | 508.41M | — |
Research & Development vs competitors
How ZEPP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.9% is the 4th highest of 7, against a peer median of -21.8%.
- Research & development amounts to 12.2% of revenue for ZEPP, versus a peer median of 16.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CN¥234.24M CNY | -27.9% | -15.5% | 12.2% | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $33.82M USD | +54.3% | +33.9% | 50.7% |
| LTM Mar 2026 | $30.54M USD | -37.0% | -2.7% | 20.0% | |
| LTM Mar 2026 | $22.49M USD | -6.6% | +14.7% | 16.1% | |
| LTM Mar 2026 | $10.08M USD | +61.6% | +36.9% | 54.3% | |
| LTM Mar 2026 | $1.95M USD | -61.5% | -17.1% | 0.3% | |
| FY2025 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding ZEPP) | — | -21.8% | +14.7% | 16.1% | |
Competitors are the stored peer set for ZEPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.17B | 4.22B | 2.5B | 1.33B | 1.82B |
| Cost of Revenue | 4.88B | 3.4B | 1.84B | 820.57M | 1.1B |
| Gross Profit | 1.29B | 817.22M | 653.7M | 512.88M | 711.63M |
| Gross Margin | 20.9% | 19.4% | 26.2% | 38.5% | 39.2% |
| Research & Development | 508.41M | 526.2M | 364.53M | 337.07M | 317.73M |
| Selling, General & Admin | 687.6M | 708.46M | 504.69M | 520.85M | 582.64M |
| Operating Expenses | 1.2B | 1.23B | 869.22M | 857.92M | 916.56M |
| Depreciation & Amortization | 51.21M | 59.65M | 54.43M | 36.64M | 31.71M |
| EBITDA | 200.8M | (261.43M) | (142.88M) | (345.66M) | (191.48M) |
| EBITDA Margin | 3.3% | -6.2% | -5.7% | -25.9% | -10.5% |
| Operating Income | 92.73M | (417.45M) | (215.52M) | (345.04M) | (204.93M) |
| Operating Margin | 1.5% | -9.9% | -8.6% | -25.9% | -11.3% |
| Interest Income | 16.47M | 12.55M | 21.86M | 26.81M | 10.7M |
| Interest Expense | 44.3M | 58M | 47.79M | 40.54M | 39.94M |
| Other Income / Expenses | 53.06M | 56.34M | (21.7M) | (108.55M) | (58.2M) |
| Income Before Tax | 145.78M | (361.11M) | (237.22M) | (453.59M) | (263.13M) |
| Pre-Tax Margin | 2.4% | -8.6% | -9.5% | -34.0% | -14.5% |
| Income Tax Expense | 10.61M | (67.03M) | (17.2M) | 99.99M | 17.79M |
| Net Income | 136.02M | (293.37M) | (220.49M) | (554.13M) | (280.92M) |
| Net Margin | 2.2% | -7.0% | -8.8% | -41.6% | -15.5% |
| EPS (Basic) | 1.38 | (2.71) | (1.96) | (34.16) | (283.04) |
| EPS (Diluted) | 1.31 | (2.71) | (1.96) | (34.16) | (283.04) |
| Weighted Avg Shares | 15.76M | 15.39M | 15.2M | 16.18M | 993.87K |
| Weighted Avg Shares (Diluted) | 16.52M | 15.39M | 15.2M | 16.18M | 993.87K |
Zepp Health Corporation
NYSE:ZEPP
Intrinsic Alpha fair value
Locked
Current Price
$3.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.